Tailong Investment
Overview
Tailong Investment is a venture capital firm founded in 2021 that focuses on investments in biopharmaceuticals, innovative medical devices, and CXO core services.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Lynk Pharmaceuticals | May 2023 | Series C | Co-investor |
| CytoCares (Shanghai) Inc. | May 2023 | Series A Extension | Co-investor |
| Immorna Biotherapeutics | Feb 2023 | Series A Extension | Co-investor |
| Leman Biotech | Mar 2026 | Series A Extension | Co-investor |
| LungHealth MedTech | Apr 2022 | Series B | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Tailong Investment based?
Tailong Investment is headquartered in Hangzhou, China.
When was Tailong Investment founded?
Tailong Investment was founded in 2021.
How many portfolio companies does Tailong Investment have?
Tailong Investment has 9 portfolio companies in Caplight's dataset.
What are some companies in Tailong Investment's portfolio?
Portfolio companies visible on Caplight include Lynk Pharmaceuticals, CytoCares (Shanghai) Inc., Immorna Biotherapeutics, Leman Biotech, LungHealth MedTech.
What was Tailong Investment's most recent investment shown here?
Tailong Investment's most recent investment in this portfolio sample was in Leman Biotech in 2026.
What sectors does Tailong Investment focus on?
Tailong Investment focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does Tailong Investment focus on?
Tailong Investment typically invests at the Early stage.